Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avenciguat by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Avenciguat is under clinical development by Boehringer Ingelheim International and currently in Phase II for Chronic Kidney Disease (Chronic Renal...
BI-690517 by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
BI-690517 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Chronic Kidney Disease (Chronic Renal...
Ezabenlimab by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
BI-1821736 by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval
BI-1821736 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Solid Tumor. According to GlobalData,...
Ezabenlimab by Boehringer Ingelheim International for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Oral Cavity (Mouth) Cancer. According...
Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval
Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...
Survodutide by Boehringer Ingelheim International for Obesity: Likelihood of Approval
Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Obesity. According to GlobalData, Phase...
Ofev by Boehringer Ingelheim International for Lymphangioleiomyomatosis: Likelihood of Approval
Ofev is under clinical development by Boehringer Ingelheim International and currently in Phase II for Lymphangioleiomyomatosis. According to GlobalData, Phase...
BI-764532 by Boehringer Ingelheim International for Neuroendocrine Cancer: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Neuroendocrine Cancer. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Glioma: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Glioma. According to GlobalData, Phase...
Empagliflozin by Boehringer Ingelheim International for Renal Stones/Calculi: Likelihood of Approval
Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Renal Stones/Calculi. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Neuroendocrine Carcinoma: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
BI-765423 by Boehringer Ingelheim International for Pulmonary Fibrosis: Likelihood of Approval
BI-765423 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pulmonary Fibrosis. According to GlobalData,...
BI-764532 by Boehringer Ingelheim International for Small-Cell Lung Cancer: Likelihood of Approval
BI-764532 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Small-Cell Lung Cancer. According to...
Zongertinib by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer. According to...
BI-905711 by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...